Last quarter (Q4 2022), Mereo Biopharma Group Plc's total revenue was £―, a decrease of ― from the same quarter last year. In Q4, Mereo Biopharma Group Plc's net income was £―. See Mereo Biopharma Group Plc’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	£ 36.46M	£ 0.00	£ 0.00	£ 0.00
Cost of Revenue	-	£ -936.00K	£ 17.91M	£ 0.00	£ 23.61M	£ 22.70M
Gross Profit	-	£ 936.00K	£ 18.56M	£ 0.00	£ -23.61M	£ -22.70M
Operating Expense	-	£ 44.51M	£ 39.49M	£ 37.57M	£ 15.91M	£ 11.78M
Operating Income	-	£ -43.57M	£ -20.94M	£ -37.57M	£ -39.52M	£ -34.48M
Net Non Operating Interest Income Expense	-	£ -2.67M	£ 4.02M	£ -6.34M	£ -4.45M	£ -2.03M
Other Income Expense	-	£ -8.62M	£ 39.20M	£ -122.54M	£ 2.85M	-
Pretax Income	-	£ -36.09M	£ 14.24M	£ -166.45M	£ -41.12M	£ -37.31M
Tax Provision	-	£ -1.90M	£ 1.52M	£ -2.82M	£ -6.27M	£ -5.28M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -34.20M	£ 12.72M	£ -163.63M	£ -34.84M	£ -32.03M
Basic EPS	-	£ -0.06	-	£ -2.40	£ -1.95	£ -2.25
Diluted EPS	-	£ -0.06	-	£ -2.40	£ -1.95	£ -2.25
Basic Average Shares	-	£ 603.20M	-	£ 67.79M	£ 17.88M	£ 14.23M
Diluted Average Shares	-	£ 603.20M	-	£ 67.79M	£ 17.88M	£ 14.23M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	£ 0.00	£ 293.00K
Total Expenses	-	£ 43.57M	£ -57.40M	£ 37.57M	£ 39.52M	£ 34.48M
Net Income From Continuing And Discontinued Operation	-	£ -34.20M	£ 12.72M	£ -163.63M	£ -34.84M	£ -32.03M
Normalized Income	-	£ -37.99M	-	£ -43.16M	£ -37.26M	£ -31.38M
Interest Expense	-	-	-	£ 6.38M	£ 4.61M	£ 3.06M
EBIT	-	£ -33.22M	£ 10.22M	£ -160.07M	£ -36.51M	£ -34.25M
EBITDA	-	£ -32.50M	-	£ -158.47M	£ -34.94M	£ -34.21M

Currency in GBP

Mereo Biopharma Group Plc Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing